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Background: Recent studies suggested that there are marked systematic differences among BNP immunoassays.
In this study we compared the BNP data and clinical results obtained with different immunoassays, including a
new method (ST-AIA-PACK, TOSOH Corporation).
Methods: BNP was measured on plasma-EDTA samples of healthy subjects (HS, n = 126) and patients with
heart failure (HF, n = 31 NYHA I, II; n = 46 NYHA III, IV) using the ST-AIA-PACK and the Triage Biosite
(Beckman Coulter) methods. Control samples distributed in the CardioOrmoCheck external quality assessment
were also measured with TOSOH and the most used BNP immunoassays in Italy.
Results: TOSOH method showed a good correlation (R = 0.976; n = 327) but a mean bias (−46.9%) compared
to Triage Biosite. On the base of the results obtained in 10 samples of the CardioOrmoCheck study, TOSOH
method showed a strict agreement with ADVIA Centaur, while it underestimated BNP in comparisonwith Triage
(−52.5%) and ARCHITECT methods (−39.4%). The agreement of ST-AIA-PACK and Triage Biosite methods for
classiﬁcation of HF patients was tested using 100 ng/L of BNP; the positive agreement between methods was
65%, overall agreement was 73%.
Conclusions: Our results conﬁrm that there are marked differences in measured values among commercial
methods for BNP assay.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cardiac natriuretic peptides, which include the Atrial Natriuretic
Peptide (ANP) and B-type natriuretic peptide (BNP) and their related
peptides, constitute a complex family of peptide hormones produced
and secreted by the human heart [1–3]. The active peptide BNP is
produced by cleavage of COOH-terminal part of the pro-hormone
(pro-BNP), while the N-terminal fragments of pro-hormone, NT-
proBNP, are currently considered inactive [1–3].
The measurement of circulating BNP and its related-peptides is
considered the best biomarker of myocardial function [1–4], and
the international guidelines recommend its use both for the diagnosis
of acute heart failure (HF), and risk stratiﬁcation and follow-up of pa-
tients with acute or chronic HF [5–7]. Moreover, some meta-analyses
[8,9] conﬁrmed that both BNP and NT-proBNP immunoassays have
a high degree of diagnostic accuracy and clinical relevance in both
acute and chronic heart failure.na, c/o Fondazione Toscana G.
+39 050 3153309; fax: +39
ini@sssup.it (M. Franzini).
rights reserved.However, recent studies suggested that a great part of B-type na-
triuretic peptides measured by commercially available immunoassays
in patients with cardiovascular disease is devoid of any biological ac-
tivity [2,3,10–12]. Results of the CardioOrmoCheck study (i.e., a proﬁ-
ciency testing program, based on an external quality assessment
scheme) recently demonstrated that there are signiﬁcant differences
in analytical characteristics and measured values among the most
popular commercial methods for B-type related natriuretic peptides,
especially among the immunossays considered speciﬁc for BNP [13,14].
In particular,more than 2 folds differencewas on average found between
the BNP values measured by the twomethods reporting the highest and
the lowest values, respectively [13,14]; while the NT-proBNP immuno-
assays showed only slightly differences in both imprecision and mea-
sured vaules. Similar results were also previously obtained by another
study performed in only one laboratory [15]. However, in spite of these
great differences in analytical and clinical performances, the most recent
international guidelines [5–7], still suggest identical decisional values
for all BNP immunoassay methods (i.e., 100 ng/L).
This pragmatical approach is actually conceivable and shearable
only if the new BNP immunoassay methods will be in agreement
with the cosensus mean of the methods available from many years
in the market. Indeed, this fact might suggest a trend of the “market”
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measured by different methods. In order to test this hypothesis
we compared with other commercially available methods the BNP
data and clinical results obtained with a new BNP immunoassay
(named ST-AIA-PACK BNP by TOSOH CORPORATION), recently brought
into market, and for this reason not evaluated in CardioOrmoCheck
studies [13,14].
2. Materials and methods
2.1. Collaborative study
The CardioOrmoCheck study is a proﬁciency testing program for the
measurement of BNP and NT-proBNP, organized in Italy since 2005
under the patronage of the Study Group of the Cardiovascular Risk
Biomarkers of the Italian Society of Clinical Biochemistry (SIBIOC) by
three accredited (ISO 9001 accreditation) Italian laboratories: CNR
QualiMedLab and Department of Laboratory Medicine of Fondazione
Toscana G.Monasterio (Pisa, Italy), Department of LaboratoryMedicine,
University-Hospital (Padova, Italy), and Biomedical Research Centre
(Castelfranco Veneto, Italy). The detailed program and study protocol
of this collaborative study have been previously described [13,14].
In the last cycle (year 2012), 112 Italian laboratories participated to
the CardioOrmoCheck study: 43 laboratories (38%) used BNP methods,
while 69 NT-proBNP methods (62%). From the 43 laboratories, which
measured the 10 study samples with BNP methods, 515 assay results
were available.
2.2. Sample preparation for the collaborative study
For the preparation of study samples, several EDTA plasma were
pooled together to obtain a sample pool with ﬁnal volume of about
100 mL, which was immediately stored at −20 °C. All samples were
tested for absence of HBsAg, antiHCV, and antiHIV. Plasma pools were
prepared using residuals from samples collected from apparently
healthy subjects (also divided according to gender) and patients with
cardiac diseases with or without symptomatic heart failure. Blood
samples collected from approximately 30–50 subjects/patientswere in-
cluded in every study sample. Subjects and patients gave the informed
consensus for the use of their residual blood samples in the study.
Study samples were sent by mail as lyophilized materials. Lyophiliza-
tion procedure was performed by Polymed (Sambuca, Firenze, Italy)
within two weeks after preparation of sample pools. Stored sample
pools, were defrozen, then distributed in approximately 150 vials
(each containing a plasma/serum volume of 0.5 mL), and ﬁnally lyoph-
ilized, as previously reported [13,14]. The lyophilized materials were
reconstituted with 0.5 mL of distilled water by participant laboratories
before the assay. BNP and NT-proBNP concentrations of all the study
samples were measured before and after the liophilization by the refer-
ence laboratory (i.e., Laboratory of the Fondazione Regione Toscana G.
Monasterio, Pisa) in order to evaluate the recovery of lyophilization
procedure and the stability of BNP and NT-proBNP in the matrix
samples. Samples with unreliable results were discarded. In particular,
only the samples with BNP and NT-proBNP values, which showed
peptide values similar to the pathophysiological characteristics of
original samples (i.e., healthy subjects, patients with moderate or
more severe heart failure) [1–3], were distributed as study samples
in the survey.
2.3. BNP measurements
BNP values were measured in the reference laboratory with the
novel ST-AIA-PACK BNP method (TOSOH Corporation, Tokyo, Japan)
and the Triage Biosite (Beckman Coulter), which is the routine method
used by the reference laboratory.The ST-AIA-PACK BNP is a two-site immunoenzymometric assay
that uses two monoclonal antibodies. Standard materials and the
antibodies are supplied by the Shionogi's Diagnostic Division (personal
communications from TOSOH EUROPE N.V., Tessenderlo, Belgium): the
capture antibody is against the ring structure (KYhBNP-II; amino acids
14–21), the detection antibody is against COOH-terminus (BC203;
amino acids 27–32) [16].
The capture antibody is immobilized on magnetic beads, while the
detection antibody is labeled with alkaline phosphatase. The magnetic
beads are washed to remove unbound enzyme-labeled monoclonal
antibody and are then incubated with the ﬂuorogenic substrate 4-
methyllumbelliferyl-phosphate. The amount of enzyme-labeled mono-
clonal antibody that binds to the beads is directly proportional to the BNP
concentration in the test sample. The ST-AIA-PACK BNP method was
performed on the AIA-2000 platform (TOSOH Corporation).
The limits of blank (LoB) and detection (LoD) and of quantitation
for ST-AIA-PACK BNP method were determined according to the CLSI
EP17-A protocol [17]. The calculated values of LoB and LoD were
2.6 ng/L and 5.4 ng/L, respectively; LoQ at 20% CV and 10% CV were
9 ng/L and 30 ng/L, respectively.
Triage Biosite (Beckman Coulter, Inc, Fullerton, CA 92835 USA)
method was performed on the UniCell DxI 800 platform. Analytical
performance of the Triage Biosite immunoassay for BNP measurement
had been previously tested in the reference laboratory and reported
elsewhere [18].
2.4. Experimental patients and samples
To evaluate and compare the analytical characteristics and clinical
results of the ST-AIA-PACK and Triage Biosite BNP methods, patients
with stable chronic heart failure, in follow up at the Fondazione
Toscana G. Monasterio, were enrolled in this study. The diagnosis
of heart failure was made according to the international guidelines
[5,6]. Cardiac morphology and function were assessed by 2D echo-
cardiography, or cardiac catheterization, when needed, as previously
described [19]. Patients were stratiﬁed according to the New York
Heart Association (NYHA) functional classiﬁcation system [19]. In
order to reduce the blood volume needed for the study and the
discomfort for the patients, BNP was measured from the residuals of
specimens obtained as standard clinical practice, and no additional
samples were obtained. All healthy people were enrolled from the lab-
oratory staff, blood donors, or voluntary subjects, included in screening
programs for preventive medicine. The informed consent was obtained
by all subjects and patients enrolled in the study.
Blood samples were collected in polypropylene tubes containing
EDTA (1 mg/mL) and aprotinine (500 kIU/mL) in the reference labo-
ratory (i.e., Laboratory of the Fondazione Toscana G. Monasterio, Pisa,
Italy). Then, samples were rapidly centrifuged at 3000 ×g for 10 mi-
nutes and plasmawas analyzed as soon as possible. If itwas not possible
to perform the assay within one hour, the samples were stored at –20 °
C until the assay.
2.5. Statistcal analysis
Standard statistical analyses were carried on by a Macintosh Dual
2.3 GHz PowerPC G5 using the Stat-View 5.0.1 program (1992–98,
SAS Institute Inc., SAS Campus Drive, Cary, NC, USA).
The agreement between BNP values measured with ST-AIA-Pack
and Triage Biosite was analysed by Bland-Altman plot. The compari-
son of BNP values among healthy subjects, patients with moderate
(functional NYHA class I and II) or severe heart failure (NYHA class III
and IV) were performed by post hoc Schiffè test after 1way-ANOVA
using log transformate of original values, because the BNP values did
not show a normal distribution, but an approximated log-normal distri-
bution. Pearson analysis has been performed to assess the correlation
between log-transformed BNP values and left ventricular ejection
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Triage Biosite methods was calculated using 100 ng/L of BNP as cut-off.
The overall agreement corresponded to the proportion of cases for
which the two BNP methods agree. The positive agreement between
methodswas calculated dividing the number of patientswith BNPvalues
over the cut-off measured with ST-AIA-PACK by those measured with
Triage Biosite method.
3. Results
3.1. Comparison between ST-AIA-PACK and Triage Biosite BNP methods
In the reference laboratory, a very close linear relationshipwas found
between the BNP values obtained measuring 327 EDTA-plasma samples
of healthy subjects and cardiac patients with ST-AIA-PACK BNP and
BNP Triage Biosite methods (Fig. 1A). However the ST-AIA-PACK
BNP method showed a signiﬁcant negative bias (i.e., underestimation)
of BNP values compared to Triage Biosite method equal to −46.9% ±
23.4% (mean ± SD, p b 0.0001) (Fig. 1B). No signiﬁcant correlationFig. 1. Comparison between ST-AIA-PACK and Triage Biosite methods. Panel A. Linear
regression found measuring 327 EDTA-plasma samples of healthy subjects and cardiac
patients with ST-AIA-PACK BNP method, using the AIA-2000 platform (Y-axis) and
BNP Triage Biosite (Beckman Coulter, Inc, Fullerton, CA 92835 USA) method using
the UniCell DxI 800 platform (Y-axis). Panel B. Scatchard plot between the percent difference
values between the BNP values obtained with ST-AIA-PACK BNP and BNP Triage Biosite
methods [(ST-AIA-PACK – Triage Biosite)/Triage Biosite x 100, Y-axis] and the BNP concen-
tration measured by BNP Triage Biosite method (X-axis). The continuous line refers to the
calculated mean difference.was found between the percentage difference [(ST-AIA-PACK – Triage
Biosite)/Triage Biosite x 100, Y-axis] and the BNP concentration
measured by the BNP Triage method (R = 0.033, p = 0.5512), while
a close correlation was found between the absolute difference of the
values obtained with the two methods and the measured BNP concen-
trations with the Triage method (R = 0.970, p b 0.0001).
The 10 study samples of the CardioOrmoCheck study, distributed
in the 2012 annual cycle, were also measured by BNP ST-AIA-PACK
in the reference laboratory in order to allow a comparison with the
most used BNP methods in Italy (Triage Biosite by Beckman Coulter,
ARCHITECT by Abbott Diagnostics and ADVIA Centaur by Siemens
Health Care) (Fig. 2). These data showed a close correlation between
the BNP values repeatedly (n = 10) measured with the ST-AIA-PACKFig. 2. Regressions between BNP methods using the study samples of CardioOrmocheck
study. Linear regressions analysis between BNP values repeatedly (n = 10) measured
with ST-AIA-PACK method by the reference laboratory and respective consensus mean
values found in the 10 study samples measured with other three methods by all laborato-
ries participating to the CardioOrmoCheck study. Panel A: Regression between
ST-AIA-PACK (Y-axis) and the BNP Triage Biosite method (Y-axis); Y = −12.7+ 0.5327
X; R = 0.9926, N = 10. Panel B: Regression between ST-AIA-PACK (Y-axis) and the
ARCHITECT method (Y-axis); Y = 7.710 + 0.5609 X; R = 0.9702, N = 10. Panel C:
Regression between ST-AIA-PACK (Y-axis) and the ADVIA Centuar method (Y-axis);
Y = −2.585 + 0.9023 X; R = 0.9981, N = 10.
Fig. 3. Distribution of BNP values in healthy subjects and patients with heart failure.
Distribition of BNP values measured with the ST-AIA-PACK method (Panel A) and Triage
Biosite method (Panel B) in 125 healthy subjects and patients with moderate (functional
NYHA class I – II, n = 31) or severe (functional NYHA classes III – IV, n = 46) heart
failure. The data are reported as boxes indicating the 25th, 50th (median), 75th percentiles
of BNP values, the whiskers correspond to the 10th, and 90th percentiles; the outliers were
indicated as separated black circles. The concentractions (Y-axis) are reported as log-scale.
The levels of statistical signiﬁcance (p values) are also indicated in the ﬁgure.
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sus mean values found with the other three methods (X-axis) by all
laboratories participating to the CardioOrmoCheck study. In particu-
lar, ST-AIA-PACK method showed a good agreement with ADVIA
Centaur method (mean difference−12.0%) (Fig. 2C), while it greatly
underestimated BNP values in comparison with both BNP Triage
Biosite (mean difference−52.5%) (Fig. 2A) and ARCHITECT methods
(mean difference −39.4%) (Fig. 2B).
3.2. Clinical results
Wemeasured the plasma concentration in 126 healthy subjects [72
males; age, mean (SD), 49.3 (11.9) years], and 76 patients with chronic
heart failure: 31 patients with moderate heart failure [functional NYHA
class I and II; 19males; age 54.9 (10.1) years; LVEF 40.3% (12.5)] and 46
patients with severe heart failure [functional NYHA class III and IV; 19
males; age 74.3 (10.9) years; LVEF 33.1% (9.5)]. Highly signiﬁcant differ-
ences (p b 0.0001) were found between the mean BNP values found
in the 3 subgroups measured with ST-AIA-PACK (Fig. 3A) or with
Triage Biosite (Fig. 3B). Log-transformed BNP values obtained with
both methods showed a negative correlation with LVEF, with similar
correlation coefﬁcients [ST-AIA-PACK: r = −0.558 (95%CI: −0.696;
−0.380), p b 0.0001; Triage Biosite: r = -0.545 (95%CI: −0.686;
−0.365)].
The agreement of ST-AIA-PACK and Triage Biosite methods for
classiﬁcation of HF patients was tested using 100 ng/L of BNP, which
is the cut-off value suggested by international guidelines [5,7]: 17 and
39 out of 77 patients showed concordant BNP values b or N100 ng/L,
respectively, with bothmethods; 21 patients showed BNP values higher
than 100 ng/L with Triage Biosite but lower with ST-AIA-PACK; no pa-
tients showed BNP values higher than the cut-off with ST-AIA-PACK
but lower with Triage Biosite. Thus overall agreement was 73% and
positive agreement (N100 ng/L) was 65%.
4. Discussion
Our results conﬁrm that large systematic differences are present
between the most popular BNP immunoassays. Indeed, wide differ-
ences between the results of BNP immunoassays had been also previ-
ously reported [13–15,20]. In particular, several studies demonstrated
that the ADVIA method for Centaur platform (by Siemens Health Care
Diagnostics) and the IRMA method (by Shionogi's Diagnostic Division,
Japan) measured lower (up to the half) BNP values in comparison
with other immunoassays, such as the POCT Triagemethod (Alere Diag-
nostics), the BNP Triage Biosite for Access and UniCell DxI platforms
(Beckam Coulter Diagnostics), the MEIA method for AxSYM system,
and the chemiluminescent microparticle immunoassay for ARCHITECT
platform (Abbotts Diagnostics) [13,14,20]. The present study demon-
strates that also the ST-AIA-PACK method for the AIA platform, only
very recently brought into market, present BNP values that are about
the half compared to other very popular BNP immunoassays, such as
the BNP Triage Biosite for UniCell DxI platform and the BNP method
for ARCHITECT platform (Figs. 2 and 3). On the other hand, this
new ST-AIA-PACK method shows BNP values similar to those found
by laboratories using the ADVIA method for Centaur platform in the
CardioOrmoCheck study (Fig. 2C). It is interesting to note that the
ST-AIA-PACK method uses the same antibodies and standard materials
of IRMA Shionogi and ADVIA method for Centaur platform, supplied by
the Shionogi's Diagnostic Division.
In conclusions, our data conﬁrm that there are marked differences
in analytical performance and measured values especially among
commercial methods for BNP assay. These ﬁndings suggest that may
be not reasonable to suggest identical cut-off or decision values for
all BNP immunoassays, as recommended by international guidelines
[5–7]. These data also suggest that clinicians should be carefullwhen comparing results obtained from different laboratories, which
use different BNP assays.Sponsorship
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